Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BAT5906 versus Lucentis in neovascular age-related macular degeneration
ChiCTR2500096858Phase 3Completed
- Sponsor
- Eye Hospital of Wenzhou Medical University
- Start
- Feb 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of BAT5906 in exudative macular degeneration (2 arms), sponsored by Eye Hospital of Wenzhou Medical University. Primary endpoint: Change from baseline in best corrected visual acuity at week 52. Started Feb 2025; status: completed.
02
Drugs
BAT5906
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on ChiCTR2500096858.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500096858.